Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
View Patent ↗Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.
1. A compound of Formula (I):
Ar 2 —SO 2 NH—Ar 1 —NHSO 2 —Ar 3 (I)
wherein
Ar 1 is a phenylene group optionally substituted 1 to 4 times, wherein the substituents of Ar 1 are selected from the group consisting of
a) -hydrogen;
b) -halo;
c) -cyano;
d) -nitro;
e) -perhaloalkyl;
I) -alkyl;
g) -aryl;
h) -heteroaryl;
i) -cycloalkyl;
j) -L-aryl;
k) -L-arylene-aryl;
l) -L-arylene-alkyl;
m) -Q-alkyl;
n) -Q-aryl;
o) -Q-alkylene-aryl;
p) -Q-arylene-alkyl;
q) -L-Q-alkylene-aryl;
r) -arylene-Q-alkyl;
s) -L-Q-alkyl;
t) -L-Q-aryl;
u) -L-Q-heteroaryl;
v) -L-Q-cycloalkyl;
w) -L-Q-arylene-alkyl;
x) -D 4 -alkylene-NR 1 R 2 ;
y) -D 4 -NR 1 R 2 ;
z) -D 4 -alkyl; and
aa) -D 4 -H;
wherein
D 4 comprises a direct bond, —CH 2 —, —O—, —N(R 4 )—, —C(O)—, —CON(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )CON(R 4′ )—, —N(R 4 )C(O)O—, —OC(O)N(R 4 )—, —N(R 4 )SO 2 —, —SO 2 N(R 4 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, —N(R 4 )SO 2 N(R 4′ )—, or —N═N—;
wherein
R 4 and R 4′ are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, -arylene-alkyl, and -alkylene-aryl;
R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, and aryl, wherein R 1 and R 2 may be taken together to form a ring having the formula —(CH 2 ) o -Z 4 -(CH 2 ) p — bonded to the nitrogen atom to which R 1 and R 2 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o+p is less than or equal to 6,
Z 4 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 31 )—, —N(C(O)R 31 )—, —N(C(O)NHR 31 )—, —N(C(O)NR 31 R 32 )—, —N(S(O) 2 NHR 31 )—, —N(SO 2 R 31 )—, or —N(C(O)OR 31 )—;
wherein
R 31 and R 32 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, and -alkylene-aryl;
L is a direct bond, -alkylene, -alkenylene , or -alkynylene; and
Q is a direct bond, —CH 2 —, —O—, or —S—;
Ar 2 is a benzothiophene group;
Ar 3 is selected from the group consisting of an aryl, heteroaryl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, and fused heterocyclylheteroaryl group,
wherein at least one of Ar 2 and Ar 3 has an oxygen atom or sulfur atom vicinal or geminal to the point of attachment to the —NHSO 2 — group, and
wherein Ar 2 and Ar 3 may be optionally substituted 1 to 5 times with a substituent selected from the group consisting of
a) -hydrogen;
b) -halo;
c) -cyano;
d) -nitro;
e) -alkyl;
f) -aryl;
g) -cycloalkyl;
h) -heterocyclyl;
i) -alkylene-cycloalkyl;
j) -perhaloalkyl;
k) heteroaryl;
l) -alkylene-aryl;
m) -D 1 -H;
n) -D 1 -R 3 ;
o) -D 1 -alkyl;
p) -D 1 -aryl;
q) -D 1 -perhaloalkyl;
r) -D 1 -alkylene-R 3 ;
s) -D 1 -alkylene-aryl;
t) -D 1 -alkylene-D 2 -R 3 ;
u) -D 1 -cycloalkyl;
v) -D 1 -heterocyclyl;
w) -D 1 -aryl;
x) -D 1 -heteroaryl;
y) -D 1 -arylene-D 2 -R 3;
z) -D 1 -heteroarylene-D 2 -R 3 ;
aa) -D 1 -alkylene-heteroaryl;
bb) -D 1 -alkylene-heterocyclyl;
cc) -D 1 -alkylene-aryl;
aa) -D 1 -alkylene-arylene-D 2 -R 3 ;
bb) -D 1 -alkylene-heteroarylene-D 2 -R 3 ;
ff) -D 1 -alkylene-NR 5 R 6 ;
gg) -D 1 -arylene-NR 5 R 6 ; and
hh) -acid isostere;
wherein
D 1 is a direct bond, —CH 2 —, —O—, —N(R 7 )—, —C(O)—, —CON(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )CON(R 8 )—, —N(R 7 )C(O)O—, —OC(O)N(R 7 )—, —N(R 7 )SO 2 —, —SO 2 N(R 7 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, —N(R 7 )SO 2 N(R 8 )—, or —N═N—;
wherein
R 7 and R 8 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;
R 3 is -hydrogen, -alkyl, -aryl, -heterocyclyl, or -heteroaryl; and
R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, and aryl, wherein R 5 and R 6 may be taken together to form a ring having the formula —(CH 2 ) o -Z 1 -(CH 2 ) p — bonded to the nitrogen atom to which R 5 and R 6 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o+p is less than or equal to 6,
Z 1 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 9 )—, —N(C(O)R 9 )—, —N(C(O)NHR 9 )—, —N(C(O)NR 9 R 10 )—, —N(S(O) 2 NHR 9 )—, —N(SO 2 R 9 )—, or —N(C(O)OR 9 )—;
wherein
R 9 and R 10 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, and -alkylene-aryl;
D 2 is -alkylene-, -alkenylene-, -alkylene-S—, —S-alkylene-, -alkylene-O—, —O-alkylene-, -alkylene-S(O) 2 —, —S(O) 2 -alkylene, —O—, —N(R 11 )—, —C(O)—, —CON(R 11 )—, —N(R 11 )C(O)—, —N(R 11 )CON(R 12 )—, —N(R 11 )C(O)O—, —OC(O)N(R 11 )—, —N(R 11 )SO 2 —, —SO 2 N(R 11 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, or —N(R 11 )SO 2 N(R 12 )—,
wherein
R 11 and R 12 are independently selected from the group consisting of -hydrogen, -alkyl, and -aryl;
and wherein
the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylene, cycloalkylene, heterocyclylene, arylene, and heteroaryl in Ar 2 , Ar 3 , R 1 through R 32 may be optionally substituted independently 1 to 4 times with a substituent group selected from the group consisting of
a) -hydrogen;
b) -halo;
c) -cyano;
d) -nitro;
e) -perhaloalkyl;
f) -A-perhaloalkyl;
g) -A-R 40 ;
h) -A-alkyl;
i) -A-aryl;
j) -A-alkylene-aryl;
k) -A-alkylene-NR 41 R 42 ; and
l) -A-alkyl-E-R 43 ;
wherein
A and E are independently selected from the group consisting of —CH 2 —, —O—, —N(R 44 )—, —C(O)—, —CON(R 44 )—, —N(R 44 )C(O)—, —N(R 44 )CON(R 45 )—, —N(R 44 )C(O)O—, —OC(O)N(R 44 )—, —N(R 44 )SO 2 —, —SO 2 N(R 44 )—, —C(O)—O—, —O—C(O)—, and —N(R 44 )SO 2 N(R 45 )—,
wherein R 44 and R 45 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;
R 40 and R 43 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl; and
R 41 and R 42 are independently selected from the group consisting of hydrogen, aryl, and alkyl, wherein R 41 and R 42 may be taken together to form a ring having the formula —(CH 2 ) o -Z 4 -(CH 2 ) p — bonded to the nitrogen atom to which R 41 and R 42 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o+p is less than or equal to 6,
Z 4 is a direct bond a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 46 )—, —N(C(O)R 46 )—, —N(C(O)NHR 46 )—, —N(C(O)NR 46 R 47 )—, —N(S(O) 2 NHR 46 )—, —N(SO 2 R 46 )—, or —N(C(O)OR 46 )—;
wherein
R 46 and R 47 are independently selected from the group consisting of hydrogen, aryl, alkyl, and -alkylene-aryl;
or a pharmaceutically acceptable salt or biohydrolyzable amide or biohydrolyzable ester thereof,
and
wherein the compound of Formula (I) is a GalR1 agonist.
2. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, wherein the —NHSO 2 —Ar 2 and the —NHSO 2 —Ar 3 substituent groups of Ar 1 are located on adjacent atoms in the Ar 1 ring.
3. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, having the formula
wherein J and K are independently selected from the group consisting of
a) -hydrogen;
b) -halo;
c) -cyano;
d) -nitro;
e) -perhaloalkyl;
f) -alkyl;
g) -aryl;
h) -heteroaryl;
i) -cycloalkyl;
j) -L-aryl;
k) -L-arylene-aryl;
l) -L-arylene-alkyl;
m) -Q-alkyl;
n) -Q-aryl;
o) -Q-alkylene-aryl;
p) -Q-arylene-alkyl;
q) -L-Q-alkylene-aryl;
r) -arylene-Q-alkyl;
s) -L-Q-alkyl;
t) -L-Q-aryl;
u) -L-Q-heteroaryl;
v) -L-Q-cycloalkyl;
w) -L-Q-arylene-alkyl;
x) -D 4 -alkylene-NR 1 R 2 ;
y) -D 4 -NR 1 R 2 ;
z) -D 4 -alkyl; and
aa) -D 4 -H;
wherein
D 4 is a direct bond, —CH 2 —, —O—, —N(R 4 )—, —C(O)—, —CON(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )CON(R 4′ )—, —N(R 4 )C(O)O—, —OC(O)N(R 4 )—, —N(R 4 )SO 2 —, —SO 2 N(R 4 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, —N(R 4 )SO 2 N(R 4′ )—, or —N═N—;
wherein R 4 and R 4′ are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, -arylene-alkyl, and -alkylene-aryl;
R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, and aryl, wherein R 1 and R 2 may be taken together to form a ring having the formula —(CH 2 ) o -Z 4 -(CH 2 ) p bonded to the nitrogen atom to which R 1 and R 2 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o+p is less than or equal to 6,
Z 4 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 31 )—, —N(C(O)R 31 )—, —N(C(O)NHR 31 )—, —N(C(O)NR 31 R 32 )—, —N(S(O) 2 NHR 31 )—, —N(SO 2 R 31 )—, or —N(C(O)OR 31 )—;
wherein
R 31 and R 32 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, and -alkylene-aryl;
L is a direct bond, -alkylene, -alkenylene, or -alkynylene; and
Q is a direct bond, —CH 2 —, —O—, or —S—.
4. The compound of Formula (I) in claim 3 , or a pharmaceutically acceptable salt thereof, wherein J and K are independently selected from the group consisting of hydrogen, halo, haloalkyl, alkoxy, haloalkoxy, cyano, carboxy, amide, -D 4 -alkyl, -D 4 -alkylene-NR 1 R 2 , -D 4 -NR 1 R 2 , -D 4 -alkyl; -D 4 -H, wherein D 4 is a —C(O)—, —CON(R 4 )—, —SO 2 N(R 4 )—, or —C(O)—O—, wherein R 4 is -hydrogen, -alkyl, -aryl, -arylene-alkyl, or -alkylene-aryl;
wherein
R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, and aryl, wherein R 1 and R 2 may be taken together to form a ring having the formula —(CH 2 ) o -Z 4 -(CH 2 ) p — bonded to the nitrogen atom to which R 1 and R 2 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o+p is less than or equal to 6,
Z 4 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 31 )—, —N(C(O)R 31 )—, —N(C(O)NHR 31 )—, —N(C(O)NR 31 R 32 )—, —N(S(O) 2 NHR 31 )—, —N(SO 2 R 31 )—, or —N(C(O)OR 31 )—;
wherein
R 31 and R 32 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, and -alkylene-aryl,
wherein at least one of J and K is a group other than hydrogen.
5. The compound of Formula (I) in claim 3 , or a pharmaceutically acceptable salt thereof, wherein Ar 2 and Ar 3 are unsubstituted benzothiophene group.
6. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 1 is an unsubstituted phenylene group.
7. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 1 is an unsubstituted phenylene group and the —NHSO 2 —Ar 2 and the —NHSO 2 —Ar 3 substituent groups are located on adjacent carbon atoms in the Ar 1 ring.
8. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 2 and Ar 3 are different.
9. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 3 is selected from the group consisting of an aryl, heteroaryl, and fused heterocyclylheteroaryl group.
10. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 3 is selected from the group consisting of an optionally substituted or unsubstituted phenyl, benzothiophenyl, benzofuranyl, or a 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl group.
11. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 3 is selected from the group consisting of an aryl, heteroaryl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, and fused heterocyclylheteroaryl group optionally substituted 1 to 5 times, wherein at least one of Ar 2 and Ar 3 is either
wherein
R 13 is alkyl, alkylene-cycloalkyl, haloalkyl, perhaloalkyl, or cycloalkyl;
R 14 is
a) -halo;
b) -cyano;
c) -nitro;
d) -perhaloalkyl;
e) -D 1 -R 17 ;
f) -D 1 -alkyl;
g) -D 1 -alkylene-R 17 ;
h) -D 1 -alkylene-D 2 -R 17 ;
i) -D 1 -aryl;
j) -D-heteroaryl;
k) -D 1 -arylene-D 2 -R 17 ;
l) -D 1 -heteroarylene-D 2 -R 17 ;
m) -D 1 -alkylene-heteroaryl;
n) -D 1 -alkylene-heterocyclyl;
o) -D 1 -alkylene-aryl;
p) -D 1 -alkylene-arylene-D 2 -R 17 ;
q) -D 1 -alkylene-heteroarylene-D 2 -R 17 ;
r) -D 1 -alkylene-NR 18 R 19 ;
s) -D 1 -arylene-NR 18 R 19 ; or
t) -acid isostere;
wherein
D 1 is a direct bond, —S(O) 2 —, —CON(R 20 )—, —SO 2 N(R 20 )—, —C(O)—O—, —S—, or —S(O)—;
wherein R 20 is -hydrogen, -alkyl, -aryl, -heterocyclyl, or -heteroaryl;
R 17 is -hydrogen, -alkyl, -aryl, -heterocyclyl, or -heteroaryl;
R 18 and R 19 are independently selected from the group consisting of hydrogen, aryl, and alkyl, wherein R 18 and R 19 may be taken together to form a ring having the formula —(CH 2 ) o -Z 2 -(CH 2 ) p — bonded to the nitrogen atom to which R 18 and R 19 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o+p is less than or equal to 6,
Z 2 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 20 )—, —N(C(O)R 20 )—, —N(C(O)NHR 20 )—, —N(C(O)NR 20 R 21 )—, —N(S(O) 2 NHR 20 )—, —N(SO 2 R 20 )—, or —N(C(O)OR 20 )—;
wherein
R 20 and R 21 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, and -alkylene-aryl;
D 2 is -alkylene-, -alkenylene-, -alkylene-S—, —S-alkylene-, -alkylene-O—, —O-alkylene-, -alkylene-S(O) 2 —, —S(O) 2 -alkylene, —O—, —N(R 22 )—, —C(O)—, —CON(R 22 )—, —N(R 22 )C(O)—, —N(R 22 )CON(R 23 )—, —N(R 22 )C(O)O—, —OC(O)N(R 22 )—, —N(R 22 )SO 2 —, —SO 2 N(R 22 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, or —N(R 22 )SO 2 N(R 23 )—,
wherein
R 22 and R 23 are independently selected from the group consisting of -hydrogen, -alkyl, and -aryl;
R 15 and R 16 are independently selected from the group consisting of
a) -hydrogen;
b) -halogen;
c) -cyano;
d) -alkyl;
e) -aryl;
f) -alkylene-aryl;
g) -D 3 -H;
h) -D 3 -alkyl;
i) -D 3 -aryl;
j) -D 3 -alkylenearyl;
k) -Y-alkyl;
l) -Y-aryl;
m) -Y-alkylene-aryl;
n) -Y-alkylene-NR 24 R 25 ; and
o) -Y-alkylene-W—R 26 ;
wherein
D 3 is —O—, —C(O)—O—, —C(O)—NH—, —SO 2 —, —SO 2 —NH—, or —C(O)—;
Y and W are independently selected from the group consisting of, —CH 2 —, —O—, —N(H), —S—, SO 2 —, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —C(O)—O—, —NHSO 2 NH—, and —O—CO—,
R 26 is aryl, alkyl, alkylene-aryl, alkoxy, or alkoxyaryl;
R 24 and R 25 are independently selected from the group consisting of hydrogen, aryl, or alkyl, wherein R 24 and R 25 may be taken together to form a ring having the formula —(CH 2 ) o -Z 3 -(CH 2 ) p — bonded to the nitrogen atom to which R 24 and R 25 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o+p is less than or equal to 6,
Z 3 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 29 )—, —N(C(O)R 29 )—, —N(C(O)NHR 29 )—, —N(C(O)NR 29 R 30 )—, —N(S(O) 2 NHR 29 )—, —N(SO 2 R 29 )—, or —N(C(O)OR 29 )—;
wherein
R 29 and R 30 are independently selected from the group consisting of hydrogen, aryl, alkyl, and -alkylaryl;
R 26 is hydrogen, alkyl, aryl, or alkylene-aryl,
X is sulfur; and
m and n are independently 0, 1, or 2.
12. The compound of Formula (I) in claim 1 , or a pharmaceutically acceptable salt thereof wherein Ar 3 is
wherein
R 14 is
a) -D 1 -perhalo C 2 -C 6 alkyl;
b) -D 1 -alkylene-heteroaryl;
c) -D 1 -alkylene-heterocyclyl;
d) -D 1 -alkylene-NR 18 R 19 ; or
e) -acid isostere.
13. The compound of Formula (I) in claim 11 , or a pharmaceutically acceptable salt thereof, wherein Ar 3 is the group
and Ar 2 is
14. The compound of Formula (I) in claim 11 , or a pharmaceutically acceptable salt thereof, wherein Ar 3 is a phenyl group substituted with at least one halo group.
15. The compound of Formula (I) in claim 11 , or a pharmaceutically acceptable salt thereof, wherein Ar 2 is the group
and
Ar 3 is a phenyl, a benzothiopheneyl, or benzofuranyl group optionally substituted 1 to 5 times,
wherein
Ar 2 and Ar 3 are the same or different.
16. The compound of Formula (I) in claim 11 , or a pharmaceutically acceptable salt thereof, wherein Ar 2 is an unsubstituted benzothiophene group.
17. A compound selected from the group consisting of:
Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide;
Benzo[b]thiophene-2-sulfonic acid {2-[2-methoxy-5-(propane-2-sulfonyl)benzenesulfonylamino]phenyl} amide;
3-[2-(Benzo[b]thiophene-2-sulfonylamino) -phenylsulfamoyl]-4-methoxy-benzoic acid methyl ester;
3-[2-(Benzo[b]thiophene-2-sulfonylamino) -phenylsulfamoyl]-4-methoxy-benzoic acid;
5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid [2-(2-methoxy-5-trifluoromethane sulfonyl-benzenesulfonylamino) -phenyl]-amide;
Benzo[b]thiophene-2-sulfonic acid [2-(5-bromo-2-methoxy-benzene sulfonylamino)-phenyl]-amide;
Benzo[b]thiophene-2-sulfonic acid [2-(4-chloro-benzenesulfonylamino)phenyl] amide;
Benzo[b]thiophene-2-sulfonic acid [2-(4-methoxy-2-nitro-benzenesulfonylamino)phenyl]amide;
Benzo[b]thiophene-2-sulfonic acid [2-(4-methanesulfonyl-2-methoxy-benzenesulfonylamino) -phenyl] amide;
Benzo[b]thiophene-2-sulfonic acid [2-(2-methoxy-5-methylbenzenesulfonylamino)phenyl] amide;
Benzo[b]thiophene-2-sulfonic acid [2-(2-methoxy-5-trifluoromethylbenzenesulfonylamino)phenyl] amide;
Benzo[b]thiophene-2-sulfonic acid {2-[5-(2-dimethylaminoethanesulfonyl)-2-methoxy-benzenesulfonylamino]phenyl} amide;
Benzo[b]thiophene-2-sulfonic acid {2-[2-methoxy-5-(2-tetrazol-2-yl-ethanesulfonyl)-benzenesulfonylamino]-phenyl}-amide;
Benzo[b]thiophene-2-sulfonic acid {2-[2-methoxy-5-(2-pyrrolidin-1-yl-ethanesulfonyl)-benzenesulfonylamino]-phenyl}-amide;
Benzo[b]thiophene-2-sulfonic acid {2-[2-methoxy-5-(2-pyrrolidin-1-yl-ethanesulfonyl)-benzenesulfonylamino]-phenyl}-amide;
Benzo[b]thiophene-2-sulfonic acid [2-(5-(1,1-Dichloro-2,2,2-trifluoroethyl)-2-methoxy-benzenesulfonylamino)phenyl] amide;
Benzo[b]thiophene-2-sulfonic acid [2-(4-imidazol-1-yl-2-methoxybenzenesulfonylamino)phenyl] amide;
N-[2-(Benzothiophene-2-sulfonyl)amino]phenylbenzothiophene-2-sulfonamide;
N-[2-(Benzothiophene-2-sulfonyl)amino]phenylbenzothiophene-2-sulfonamide;
N,N′-(4-fluoro-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide);
N,N′-(4-cyano-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide);
2-[2-(Benzo[b]thiophene-2-sulfonylamino)-phenylsulfamoyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylic acid tert-butyl ester;
N,N′-(4,5-dichloro-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide);
N,N′-(4-trifluoromethyl-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide);
N,N′-(4-chloro-5-fluoro-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide);
N,N′-(4,5-fluoro-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide);
Benzo[b]thiophene-2-sulfonic acid [2-(5-cyano-2-methoxy-benzenesulfonylamino)-phenyl]-amide;
Benzo[b]thiophene-2-sulfonic acid {2-[2-methoxy-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzenesulfonylamino]-phenyl}-amide;
N,N′-(4-chloro-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide);
N,N′-(4-bromo-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide); and
N,N′-(4-methoxy-1,2-phenylene)bis(1-benzothiophene-2-sulfonamide), or a pharmaceutically acceptable salts thereof.
18. A pharmaceutical composition comprising the compound of Formula (I) as in claim 1 , or a pharmaceutically acceptable salt thereof
19. The pharmaceutical composition of claim 18 , further comprising a pharmaceutically suitable carrier, excipient, diluent, or mixture thereof.
20. The pharmaceutical composition of claim 18 , wherein the compound of Formula (I) , or a pharmaceutically acceptable salt thereof, is present in an amount sufficient to increase activity of a GalR1 receptor.
21. The pharmaceutical composition of claim 18 , wherein the compound of Formula (I) , or a pharmaceutically acceptable salt thereof, is present in an amount sufficient to stimulate GalR1 in a subject.
22. The pharmaceutical composition of claim 18 , comprising a therapeutically effective amount of a compound of Formula (I) , or a pharmaceutically acceptable salt thereof, wherein said therapeutically effective amount is an amount of the compound of Formula (I) capable of at least partially activating the GalR1 receptor in a subject.
23. The pharmaceutical composition of claim 18 in the form of an oral dosage unit.
24. The pharmaceutical composition of claim 18 in the form of a parenteral dosage unit.
25. The pharmaceutical composition of claim 18 , further comprising one or more additional therapeutic agents.
26. The pharmaceutical composition of claim 25 , further comprising one or more therapeutic agents selected from the group consisting of biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV inhibitors, GK activators, insulin, insulin mimetics, insulin secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics, cholinesterase inhibitors, antipsychotics, antidepressants, anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, and fibrates.
27. The pharmaceutical composition of claim 25 , further comprising one or more therapeutic agents selected from the group consisting of anticancer agents.
28. A pharmaceutical composition comprising the compound of Formula (I) as in claim 2 , or a pharmaceutically acceptable salt thereof.
29. A pharmaceutical composition comprising the compound of Formula (I) as in claim 3 , or a pharmaceutically acceptable salt thereof.
30. A pharmaceutical composition comprising the compound of Formula (I) as in claim 4 , or a pharmaceutically acceptable salt thereof.
31. A pharmaceutical composition comprising the compound of Formula (I) as in claim 5 , or a pharmaceutically acceptable salt thereof.
32. A pharmaceutical composition comprising the compound of Formula (I) as in claim 6 , or a pharmaceutically acceptable salt thereof.
33. A pharmaceutical composition comprising the compound of Formula (I) as in claim 7 , or a pharmaceutically acceptable salt thereof.
34. A pharmaceutical composition comprising the compound of Formula (I) as in claim 8 , or a pharmaceutically acceptable salt thereof.
35. A pharmaceutical composition comprising the compound of Formula (I) as in claim 9 , or a pharmaceutically acceptable salt thereof.
36. A pharmaceutical composition comprising the compound of Formula (I) as in claim 10 , or a pharmaceutically acceptable salt thereof.
37. A pharmaceutical composition comprising the compound of Formula (I) as in claim 11 , or a pharmaceutically acceptable salt thereof.
38. A pharmaceutical composition comprising the compound of Formula (I) as in claim 12 , or a pharmaceutically acceptable salt thereof.
39. A pharmaceutical composition comprising the compound of Formula (I) as in claim 13 , or a pharmaceutically acceptable salt thereof.
40. A pharmaceutical composition comprising the compound of Formula (I) as in claim 14 , or a pharmaceutically acceptable salt thereof.
41. A pharmaceutical composition comprising the compound of Formula (I) as in claim 15 , or a pharmaceutically acceptable salt thereof.
42. A pharmaceutical composition comprising the compound of Formula (I) as in claim 16 , or a pharmaceutically acceptable salt thereof.
43. A pharmaceutical composition comprising the compound of Formula (I) as in claim 17 , or a pharmaceutically acceptable salt thereof.
44. A compound of Formula (Ia)
wherein
wherein J and K are independently selected from the group consisting of
a) -hydrogen;
b) -halo;
c) -cyano;
d) -nitro;
e) -perhaloalkyl;
f) -alkyl;
g) -aryl;
h) -heteroaryl;
i) -cycloalkyl;
j) -L-aryl;
k) -L-arylene-aryl;
l) -L-arylene-alkyl;
m) -Q-alkyl;
n) -Q-aryl;
o) -Q-alkylene-aryl;
p) -Q-arylene-alkyl;
q) -L-Q-alkylene-aryl;
r) -arylene-Q-alkyl;
s) -L-Q-alkyl;
t) -L-Q-aryl;
u) -L-Q-heteroaryl;
v) -L-Q-cycloalkyl;
w) -L-Q-arylene-alkyl;
x) -D 4 -alkylene-NR 1 R 2 ;
y) -D 4 -NR 1 R 2 ;
z) -D 4 -alkyl; and
aa) -D 4 -H;
wherein
D 4 is a direct bond, —CH 2 —, —O—, —N(R 4 )—, —C(O)—, —CON(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )CON(R 4′ )—, —N(R 4 )C(O)O—, —OC(O)N(R 4 )—, —N(R 4 )SO 2 —, —SO 2 N(R 4 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, —N(R 4 )SO 2 N(R 4′ )—, or —N═N—;
wherein R 4 and R 4′ are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, -arylene-alkyl, and -alkylene-aryl;
R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, and aryl, wherein R 1 and R 2 may be taken together to form a ring having the formula —(CH 2 ) o -Z 4 -(CH 2 ) p — bonded to the nitrogen atom to which R 1 and R 2 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o +p is less than or equal to 6,
Z 4 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 31 )—, —N(C(O)R 31 )—, —N(C(O)NHR 31 )—, —N(C(O)NR 31 R 32 )—, —N(S(O) 2 NHR 31 )—, —N(SO 2 R 31 )—, or —N(C(O)OR 31 )—;
wherein
R 31 and R 32 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, and -alkylene-aryl;
L is a direct bond, -alkylene, -alkenylene , or -alkynylene;
Q is a direct bond, —CH 2 —, —O—, or —S—;
Ar 2 is
and
Ar 3 is either
wherein
R 13 is alkyl, alkylene-cycloalkyl, haloalkyl, perhaloalkyl, or cycloalkyl;
R 14 is
a) -halo;
b) -cyano;
c) -nitro;
d) -perhaloalkyl;
e) D 1 -R 17 ;
f) -D 1 -alkyl;
g) -D 1 -alkylene-R 17 ;
h) -D 1 -alkylene-D 2 -R 17 ;
i) -D 1 -aryl;
j) -D 1 -heteroaryl;
k) -D 1 -arylene-D 2 -R 17 ;
l) -D 1 -heteroarylene-D 2 -R 17 ;
m) -D 1 -alkylene-heteroaryl;
n) -D 1 -alkylene-heterocyclyl;
o) -D 1 -alkylene-aryl;
p) -D 1 -alkylene-arylene-D 2 -R 17 ;
q) -D 1 -alkylene-heteroarylene-D 2 -R 17 ;
r) -D 1 -alkylene-NR 18 R 19 ;
s) -D 1 -arylene-NR 18 R 19 ;
t) -D 1 -perhalo C 2 -C 6 alkyl; or
u) -acid isostere;
wherein
D 1 is a direct bond, —S(O) 2 —, —CON(R 20 )—, —SO 2 N(R 20 )—, —C(O)—O—, —S—, or —S(O)—;
wherein R 20 is -hydrogen, -alkyl, -aryl, -heterocyclyl, or -heteroaryl;
R 17 is -hydrogen, -alkyl, -aryl, -heterocyclyl, or -heteroaryl;
R 18 and R 19 are independently selected from the group consisting of hydrogen, aryl, and alkyl, wherein R 18 and R 19 may be taken together to form a ring having the formula —(CH 2 ) o -Z 2 -(CH 2 ) p — bonded to the nitrogen atom to which R 18 and R 19 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o +p is less than or equal to 6,
Z 2 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 20 )—, —N(C(O)R 20 )—, —N(C(O)NHR 20 )—, —N(C(O)NR 20 R 21 )—, —N(S(O) 2 NHR 20 )—, —N(SO 2 R 20 )—, or —N(C(O)OR 20 )—;
wherein
R 20 and R 21 are independently selected from the group consisting of -hydrogen, -alkyl, -aryl, and -alkylene-aryl;
D 2 is -alkylene-, -alkenylene-, -alkylene-S—, —S-alkylene-, -alkylene-O—, —O—alkylene-, -alkylene-S(O) 2 —, —S(O) 2 -alkylene, —O—, —N(R 22 )—, —C(O)—, —CON(R 22 )—, —N(R 22 )C(O)—, —N(R 22 )CON(R 23 )—, —N(R 22 )C(O)O—, —OC(O)N(R 22 )—, —N(R 22 )SO 2 —, —SO 2 N(R 22 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, or —N(R 22 )SO 2 N(R 23 )—,
wherein
R 22 and R 23 are independently selected from the group consisting of -hydrogen, -alkyl, and -aryl;
R 15, R 16 and R 33 are independently selected from the group consisting of
a) -hydrogen;
b) -halogen;
c) -cyano;
d) -alkyl;
e) -aryl;
f) -alkylene-aryl;
g) -D 3 -H;
h) -D 3 -alkyl;
i) -D 3 -aryl;
j) -D 3 -alkylenearyl;
k) -Y-alkyl;
l) -Y-aryl;
m) -Y-alkylene-aryl;
n) -Y-alkylene-NR 24 R 25 ; and
o) -Y-alkylene-W—R 26 ;
wherein
D 3 is —O—, —C(O)—O—, —C(O)—NH—, —SO 2 —, —SO 2 —NH—, or —C(O)—;
Y and W are independently selected from the group consisting of —CH 2 —, —O—, —N(H), —S —, SO 2 —, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —C(O)—O—, —NHSO 2 NH—, and —O—CO—,
R 26 is aryl, alkyl, alkylene—aryl, alkoxy, or alkoxyaryl;
R 24 and R 25 are independently selected from the group consisting of hydrogen, aryl, and alkyl, wherein R 24 and R 25 may be taken together to form a ring having the formula —(CH 2 ) o -Z 3 -(CH 2 ) p — bonded to the nitrogen atom to which R 24 and R 25 are attached,
wherein
o and p are, independently, 1, 2, 3, or 4 and o +p is less than or equal to 6,
Z 3 is a direct bond, —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O) 2 —, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O) 2 N(H)—, —(O)CO—, —NHS(O) 2 NH—, —OC(O)—, —N(R 29 )—, —N(C(O)R 29 )—, —N(C(O)NHR 29 )—, —N(C(O)NR 29 R 30 )—, —N(S(O) 2 NHR 29 )—, —N(SO 2 R 29 )—, or —N(C(O)OR 29 )—;
wherein
R 29 and R 30 are independently selected from the group consisting of hydrogen, aryl, alkyl, and -alkylaryl;
R 26 is hydrogen, alkyl, aryl, or alkylene-aryl,
X is sulfur or oxygen; and
m and n are independently 0, 1, or 2,
or a pharmaceutically acceptable salt thereof,
and
wherein the compound of Formula (I) is a GalR 1 agonist.
45. The compound of Formula (I) in claim 44 , or a pharmaceutically acceptable salt thereof, wherein Ar 3 is
wherein
R 14 is
a) -D 1 -perhalo C 2 -C 6 alkyl;
b) -D 1 -alkylene-heteroaryl;
c) -D 1 -alkylene-heterocyclyl;
d) -D 1 -alkylene-NR 18 R 19 ; or
e) -acid isostere.
46. The compound of Formula (I) in claim 44 , or a pharmaceutically acceptable salt thereof, wherein Ar 3 is a phenyl group substituted with at least one halo group.
47. The compound of Formula (I) in claim 44 , or a pharmaceutically acceptable salt thereof, wherein Ar 2 is the group
and
Ar 3 is a phenyl, a benzothiopheneyl, or benzofuranyl group optionally substituted 1 to 5 times,
wherein
Ar 2 and Ar 3 are the same or different.
48. The compound of Formula (I) in claim 44 , or a pharmaceutically acceptable salt thereof, wherein Ar 2 is an unsubstituted benzothiophene group.
49. A pharmaceutical composition comprising the compound of Formula (Ia) as in claim 44 , or a pharmaceutically acceptable salt thereof.
50. A pharmaceutical composition comprising the compound of Formula (Ia) as in claim 45 , or a pharmaceutically acceptable salt thereof.
51. A pharmaceutical composition comprising the compound of Formula (Ia) as in claim 46 , or a pharmaceutically acceptable salt thereof.
52. A pharmaceutical composition comprising the compound of Formula (Ia) as in claim 47 , or a pharmaceutically acceptable salt thereof.
53. A pharmaceutical composition comprising the compound of Formula (Ia) as in claim 48 , or a pharmaceutically acceptable salt thereof.